Company Overview and News

Vehicle registrations edge higher in November: JB Securities

2016-12-26 lankabusinessonline
Dec 26, 2016 (LBO) – Sri Lanka vehicle registrations edged higher in November compared with October, on most categories, likely driven by pre-budget demand, JB Securities said in a research note.

Sri Lanka vehicle registrations rebound from July lows: JB

2016-09-19 lankabusinessonline
Sept 19, 2016 (LBO) – Sri Lanka vehicle registrations saw a rebound in August from the July lows in the categories of small cars, three-wheelers, two-wheelers and mini trucks, JB Securities said.

India made vehicles remain at top in Sri Lanka even as overall registration figures fall

India-made vehicles have managed to remain at the top in new motor vehicle registration in Sri Lanka even as registrations as a whole hit a new low, data collected by JB Securities for the month of July show.

Sri Lanka vehicle registrations fall further in July: JB Securities

2016-08-16 lankabusinessonline
Aug 16, 2016 (LBO) – Sri Lanka vehicle registrations in July fell in almost every category compared with June, JB Securities said in a research note. Buses and heavy truck registrations however showed an increase over the previous month.

Lackadaisical trend in Sri Lanka vehicle registrations in Feb: JB Sec.

2016-03-25 lankabusinessonline
Mar 25, 2016 (LBO) – The lackadaisical trend from January has continued into February with the 70 percent LTV rule, significant increases in tariffs, continuing weakness in the rupee, surprising strength in the Yen and rising interest rates have retarded volumes, JB Securities said in a research note.

Sri Lanka motor car registrations drop to 7,177 in Dec: JB

2016-01-25 lankabusinessonline
Jan 25, 2015 (LBO) - Sri Lanka's vehicle registration momentum came down in Dec with the reinstatement of the LTV rule and higher incidence of duty on vehicles, JB Securities said in a research not...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...